Chapter 1. Research Objective
1.1 Objective, Definition & Scope
1.2 Methodology
1.2.1 Primary Research
1.2.2 Secondary Research
1.2.3 Market Forecast - Estimation & Approach
1.2.4 Assumptions & Assessments
1.3 Insights and Growth - Relevancy Mapping
1.3.1 FABRIC Platform
1.4 Data mining & efficiency
Chapter 2. Executive Summary
2.1 Anti-Viral Therapies Market Overview
2.2 Interconnectivity & Related markets
2.3 Ecosystem Map
2.4 Anti-Viral Therapies Market Business Segmentation
2.5 Anti-Viral Therapies Market Geographic Segmentation
2.6 Competition Outlook
2.7 Key Statistics
Chapter 3. Strategic Analysis
3.1 Anti-Viral Therapies Market Revenue Opportunities
3.2 Cost Optimization
3.3 Covid19 aftermath - Analyst view
3.4 Anti-Viral Therapies Market Digital Transformation
Chapter 4. Market Dynamics
4.1 DROC
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PEST Analysis
4.2.1 Political
4.2.2 Economic
4.2.3 Social
4.2.4 Technological
4.3 Market Impacting Trends
4.3.1 Positive Impact Trends
4.3.2 Adverse Impact Trends
4.4 Porter's 5-force Analysis
4.5 Market News - By Segments
4.5.1 Organic News
4.5.2 Inorganic News
Chapter 5. Market Segmentation
The Anti-Viral Therapies Market has been analysed to include the below segmentation:
BY APPLICATION
• HIV
• Hepatitis
• Herpes
• Influenza
• Others
BY TYPE
• Generic drugs
• Branded drugs
BY MECHANISM OF ACTION
• Nucleotide polymerase inhibitor
• Reverse transcriptase inhibitors
• Protease inhibitors
• Others
Chapter 5A. Regional Segmentation
The Anti-Viral Therapies Market has been analysed by studying the following regions:
North America
• BY APPLICATION
• BY TYPE
• BY MECHANISM OF ACTION
Europe
• BY APPLICATION
• BY TYPE
• BY MECHANISM OF ACTION
APAC
• BY APPLICATION
• BY TYPE
• BY MECHANISM OF ACTION
LatAm
• BY APPLICATION
• BY TYPE
• BY MECHANISM OF ACTION
MEA
• BY APPLICATION
• BY TYPE
• BY MECHANISM OF ACTION
**The Regions are further studied to analyse the major countries within the respective regions. The coverage of the country level data is dynamic and is updated regularly based on the market movements. Normally, the countries covered in the report include:
• North America - United States, Canada, Mexico;
• Europe - United Kingdom, France, Italy, Germany, Spain, Rest of Europe;
• Asia Pacific - China, India, Japan, South Korea, Rest of APAC;
• Middle East & Africa - South Africa, GCC Countries, Rest of MEA;
• Latin America - Brazil, Argentina, Rest of LatAm;
Chapter 6. Market Use case studies
Chapter 7. KOL Recommendations
Chapter 8. Investment Landscape
8.1 Anti-Viral Therapies Market Investment Analysis
8.2 Market M&A
8.3 Market Fund Raise & Other activity
Chapter 9. Anti-Viral Therapies Market - Competitive Intelligence
9.1 Company Positioning Analysis
9.1.1 Positioning - By Revenue
9.1.2 Positioning - By Business Score
9.1.3 Legacy Positioning
9.2 Competitive Strategy Analysis
9.2.1 Organic Strategies
9.2.2 Inorganic Strategies
Chapter 10. Key Company Profiles
*The Anti-Viral Therapies Market Report profiles companies based on the material impact they have on the market ecosystem. These are hence, to be read as 'Key Players' and not necessarily 'Market Leaders'.
Companies are typically profiled to include:
10.x.1 Company Fundamentals
10.x.2 Performance Overview
10.x.3 Product Overview
10.x.4 Recent Developments
Key Companies profiled in this report include:
• ABBOTT LABORATORIES
• ABBVIE INC.
• BRISTOL MYERS SQUIBB COMPANY
• F. HOFFMANN-LA ROCHE LTD.
• JOHNSON & JOHNSON
• MERCK & CO., INC.
• GILEAD SCIENCES, INC.
• GlaxoSmithKline Plc.
• ASTRAZENECA PLC
• AUROBINDO PHARMA LIMITED
Chapter 11. Appendix
11.1 About AllTheResearch (ATR)
11.2 ATR Services
11.3 Author details
11.4 Terms & Conditions
11.5 Contact us